Clinical trial
Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety, Tolerability, PK/PD of SAD, MAD and Food Effect of Leucettinib-21 in Healthy Male Subjects, and Single Dose in Subjects With Down Syndrome or Alzheimer's Disease
NCT06206824 is registered in ClinicalTrials.gov with Perha Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety, Tolerability, PK/PD of SAD, MAD and Food Effect of Leucettinib-21 in Healthy Male Subjects, and Single Dose in Subjects With Down Syndrome or Alzheimer's Disease
- Lead sponsor
- Perha Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 18, 2024
- Completion date
- June 25, 2026
- Enrollment
- 152 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease, down syndrome, healthy volunteers